RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Cholangiocarcinoma Clinical Trial

— EPIC  

Official title:

A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02452970
• Other study ID #: RRx001-27-01
• Status: Terminated
• Phase: Phase 2
• Start date: July 16, 2015
• Est. completion date: May 25, 2016

Study information

• Verified date: March 2024
• Source: EpicentRx, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them re-respond to gemcitabine and cisplatin, which, hopefully, will translate to a longer lifespan. The name of the open-label study, which means that patients will know what treatments they are receiving, is EPIC, a hybrid or combination of EPIgenetic for the mechanism of action of RRx-001 and Cholangiocarcinoma.

The study treatment is divided into two stages. During the first stage, patients will receive RRx-001, which is administered intravenously weekly, for a fixed time period of six weeks. At that time the second stage starts in which cisplatin and gemcitabine are reintroduced for as long as the tumors respond to them to determine whether resensitization has occurred.

The primary objective of this clinical trial is to evaluate the progression-free survival (PFS) of patients at 9 weeks after the reintroduction of gemcitabine and cisplatin.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: May 25, 2016
• Est. primary completion date: May 10, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma

• Must have locally advanced or distant metastatic disease that is not surgically curable

• Failed first-line chemotherapy

• Age = 18 years

• Life expectancy of at least 12 weeks (3 months)

• Performance status 0 or 1

• Adequate liver, kidney, and bone marrow function

Exclusion Criteria:

• Symptomatic metastatic brain or meningeal tumors

• Investigational compound within 4 weeks of enrollment

• History of needing to permanently discontinue prior gemcitabine/ cisplatin regimen for reasons other than progression (i.e. toxicity)

• Any medical condition which, in the investigator's opinion, makes the patient unsuitable for participation

• Pregnant or nursing

• Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results

• Albumin <2.8

• Uncontrolled or clinically relevant ascites

• Absolute contraindication for MRI imaging such as intracorporeal metal or pacemaker

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• RRx-001
RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
• Gemcitabine and cisplatin
RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression

Locations

Country	Name	City	State
United States	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
EpicentRx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Objective Response (RECIST)	Overall objective response (RECIST)	Baseline and every 6-8 weeks while on treatment until progression. Estimated 8 -24 weeks.